Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott Victor Bratman, S.Y. Cindy Yang, Marco Adelmo James Iafolla et al. · Nature Cancer · 2020
Cited by 485 works. doi:10.1038/s43018-020-0096-5
Authors
- Scott Victor Bratman
- S.Y. Cindy Yang
- Marco Adelmo James Iafolla
- Zhihui Liu
- Aaron Richard Hansen
- Philippe Lucien Bedard
- Stéphanie Lheureux
- Anna Spreafico
- Albiruni Abdul Razak
- Svetlana Shchegrova
- Maggie C. Louie
- Paul R. Billings
- Bernhard G Zimmermann
- Himanshu Sethi
- Alexey A. Aleshin
- Dax Torti
- Kayla Marsh
- Jenna Eagles
- Iulia Cirlan
- Youstina Hanna
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
- Integrated digital error suppression for improved detection of circulating tumor DNA
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy